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Long noncoding RNALong noncoding RNAs (lncRNAs) are emerging as important regulators of developmental pathways. However,
their roles in human cardiac precursor cell (CPC) remain unexplored. To characterize the long noncoding tran-
scriptome during human CPC cardiac differentiation, we proﬁled the lncRNA transcriptome in CPCs isolated
from the human fetal heart and identiﬁed 570 lncRNAs that were modulated during cardiac differentiation.
Many of these were associated with active cardiac enhancer and super enhancers (SE) with their expression
being correlated with proximal cardiac genes. One of themost upregulated lncRNAs was a SE-associated lncRNA
that was named CARMEN, (CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA. CARMEN exhibits
RNA-dependent enhancing activity and is upstream of the cardiac mesoderm-specifying gene regulatory net-
work. Interestingly, CARMEN interacts with SUZ12 and EZH2, two components of the polycomb repressive com-
plex 2 (PRC2). We demonstrate that CARMEN knockdown inhibits cardiac speciﬁcation and differentiation in
cardiac precursor cells independently ofMIR-143 and -145 expression, two microRNAs located proximal to the
enhancer sequences. Importantly, CARMEN expression was activated during pathological remodeling in the
mouse and human hearts, and was necessary for maintaining cardiac identity in differentiated cardiomyocytes.
This study demonstrates therefore that CARMEN is a crucial regulator of cardiac cell differentiation and homeostasis.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The postnatal heart has minimal regenerative potential, and heart
failure typically develops following injury [1]. Currently, heart trans-
plantation remains the only viable therapeutic option for end-stage
heart failure. Within this context, cell replacement therapy via injection
of precursor cells into the damagedmyocardium to promote cardiac re-
generation and prevent pathological remodeling represents an attrac-
tive therapeutic approach [2]. However, the main challenge for
utilizing cell therapies for heart disease in a clinical setting is the identi-
ﬁcation of a suitable source of human cardiac precursor cells (CPCs) that
give rise to functionally integrated cardiomyocytes (CMs). TheUnit, Department of Medicine,
e, Switzerland.
), rory.johnson@crg.es
. This is an open access article underexistence of resident CPCs in the adult mammalian heart, including
the human heart, capable of differentiating into mature CMs has been
demonstrated [2]. However, the number of CPCs in the adult heart is
low and expansion of human CPCs in culture is amandatory step to pro-
duce sufﬁcient numbers of precursors for cell therapies. Furthermore,
our relative inefﬁciency to induce robust differentiation of CPCs into
functional CMs in vivo is a severe limitation to clinical application.
Therefore, to promote cardiac regeneration, it is imperative to improve
our understanding of the molecular pathways and regulatory circuitry
that controls recruitment and differentiation of CPCs toward the cardiac
lineage.
At the molecular level, cardiac speciﬁcation and differentiation is a
complex biological process dictated by the activity of gene regulatory
networks (GRNs). Cardiac GRNs are under the control of the core tran-
scription factors (TFs), including NKX2.5, GATA4, MESP1, MEF2C and
TBOX proteins [3]. These factors interact in a combinatorial manner
with chromatin remodeling complexes to target cis-regulatory se-
quences and elicit speciﬁc temporal and spatial gene expressionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protein-based regulatory systems has been somewhat premature [4].
Several recent studies have demonstrated that gene regulatory network
activity is under the control of diverse noncoding RNAs (ncRNAs) [5,6].
These ncRNAs control numerous aspects of GRN activity including tran-
scriptional control, post-transcriptional processing, and chromatin re-
modeling [6]. Currently, the best characterized ncRNAs in the heart
are themicroRNAs (miRNAs), whichﬁne tunemRNAexpression though
post-transcriptional silencing [5]. However, the recent advent of unbi-
ased high-throughput RNA-sequencing (RNA-Seq) has led to the dis-
covery of the numerically greater and more diverse class of long
noncoding RNAs (lncRNAs) [7,8]. LncRNAs are transcripts that are oper-
ationally deﬁned as being larger than 200 nucleotides in size and that
lack discernible protein coding potential. Latest estimates have more
than 15,000 such transcripts in human gene collections (GENCODEv22),
a number which continues to rise with accumulating data from cell-
speciﬁc RNA-Sequencing (RNA-Seq) [4,7]. Less than 1% of human
lncRNAs have so far been characterized experimentally [9]. However,
an increasingly signiﬁcant number have been shown to play diverse
regulatory roles in the nucleus and cytoplasm. These include chromo-
some X inactivation, genomic imprinting, splicing, transcriptional regu-
lation and targeting of epigenetic chromatin modifying complexes to
speciﬁc genomic loci [4].
LncRNAswere originally annotated based on their genomic location.
However, functional annotations based on underlying chromatin states
have recently emerged. A class of lncRNAs has been associated with ac-
tive enhancer states (H3K27Ac/H3K4me1/p300), and these are classi-
ﬁed as enhancer-associated lncRNAs [10,11]. Interestingly, these
transcripts are able to modulate gene expression both in cis and trans,
expanding the canonical roles of enhancer sequences. Enhancers are
an important but enigmatic class of regulatory sequences, which are
the key information processing units that integrate temporal, spatial
and environmental cues within the genome [12]. Importantly, chroma-
tin looping and promoter pause/release, both important processes that
mediate enhancer-promoter communication are dependent on the pro-
duction of enhancer-derived ncRNAs [13]. Recently, a novel class of en-
hancers has been described, the class of super enhancers (SE) [14,15].
SEs are much larger than classical enhancers (typically 1–10 kbp in
size) and aremaster regulators of cell identity genes, including develop-
mental TFs and other components determining cell-speciﬁc biology.
Their function is associated with increased production of enhancer-
associated ncRNAs as well as enrichment of speciﬁc histone modiﬁca-
tions and chromatin remodeling complexes [14,15]. Not surprisingly, a
number of important lineage-determining lncRNAs are derived from
tissue-speciﬁc SEs [16,17].
Within this context, lncRNAs are emerging as an important class
of regulatory mediators of cardiac lineage-speciﬁc commitment dur-
ing development and of specialized cellular functions involved in
maintaining cardiac integrity [18–24]. Two recently described
lncRNAs, Braveheart (Bvht) and Fendrr, were shown to be key regula-
tors of cardiac mesoderm speciﬁcation and subsequent differentia-
tion via their ability to epigenetically modulate the expression of
important cardiac transcription factors [18,19]. Recent studies have
also identiﬁed thousands of novel human and mouse heart enriched
lncRNAs modulated in the adult heart post injury, implicating these
in the pathological response [21–23,25], and highlighting their po-
tential utility as biomarkers [21,22,24,26]. Moreover, considering
the unique characteristics of SEs, cardiac lncRNAs associated with
SE sequences are likely to be functionally important and relevant
modulators of cardiac speciﬁcation and differentiation. However,
the roles of lncRNAs, and speciﬁcally SE-associated lncRNAs, in
human CPCs have not been investigated. Therefore, there is a clear
need to identify cardiogenic lncRNAs important in human development
and CPC differentiation. In this study, we have identiﬁed and character-
ized CARMEN, a SE-associated lncRNA important for cardiac speciﬁca-
tion and differentiation in human CPCs.2. Results
2.1. Proﬁling of the transcriptome in differentiating CPCs identiﬁes differen-
tially expressed lncRNAs
To address the role of lncRNAs in human CPC speciﬁcation, differen-
tiation and maturation, we ﬁrst identiﬁed lncRNAs that were differen-
tially expressed in human CPCs upon differentiation. CPCs were
isolated from the fetal human heart as previously described [27].
These cells expressed early cardiac marker such as NKX2.5 and GATA4
but not proteins expressed by fully differentiated CMs, smooth muscle
cells and endothelial cells (Suppl. Fig. 1A). CPCs were then induced to
differentiate into CMs in vitro using an establishedmethod. Cardiac dif-
ferentiation was associated with increased expression of mature CM
marker genes includingMYH6, CAv1.2 and RYR2 (Fig. 1A). This protocol
typically resulted in efﬁcient cardiac differentiation, with up to 16% of
NKX2.5- and α-actinin-positive CMs presenting organized sarcomeres
following seven days of differentiation (Fig. 1B).We therefore extracted
RNA from undifferentiated (proliferating) and differentiated cell cul-
tures and hybridized RNA samples to custom microarrays targeting es-
sentially every transcript in the recently published GENCODEv7 lncRNA
catalogue [7]. The majority of the lncRNAs that are in the GENCODEv7
catalogue are spliced, polyadenylated and primarily annotated based
on ESTs and cDNAs from oligo-dT reverse transcribed cDNA libraries
[7]. The array comprised four distinct, strand-speciﬁc probes against
14,880 transcripts, in addition to a set of 3231 randomly selected probes
targeting human mRNAs.
We used a linearmodel approach to identify differentially expressed
transcripts between proliferating and differentiated CPCs, taking advan-
tage of the limma package for differential gene expression analysis [28].
This identiﬁed 570 (266 down- and 304 upregulated) differentially
expressed lncRNAs during CPC differentiation at a false discovery rate
(FDR) of b0.05 (Fig. 1C, Suppl. Table S2). Unsupervised hierarchical clus-
tering of lncRNA and mRNA expression segregates the undifferentiated
CPCs from differentiated CPCs (Fig. 1D), conﬁrming that the differentia-
tion process in vitro led to a robust change in the cardiac noncoding
transcriptome. Consistent with previous reports in other tissues [7],
lncRNAs in CPCs were detected at lower levels than mRNA (Suppl. Fig.
1B) and displayed a comparable lack of protein coding potential when
compared to GENCODE mRNAs and lncRNAs (Suppl. Fig. 1C). Differen-
tially expressed lncRNAs encompassed the various subtypes of lncRNAs
(Fig. 1E) based on genomic geography with respect to proximal coding
genes (i.e. intragenic vs. intergenic; exonic vs. intronic; sense vs. anti-
sense; overlapping vs. non-overlapping). There were no signiﬁcant dif-
ferences in the conservation status of modulated lncRNAs with most
being either highly or poorly conserved across 21 mammalian species
(Suppl. Fig. 1D). However, as previously observed lncRNA exons were
signiﬁcantly less conserved than coding exons from mRNAs, although
promoter sequences were equally well conserved between these two
classes of transcripts (Suppl. Fig. 1E). In order to determine the expres-
sion patterns and tissue speciﬁcity of themodulated lncRNAs,we exam-
ined their expression in a wide variety of human tissues using available
custom GENCODEv7 lncRNA array datasets [7]. Tissue-speciﬁc enrich-
ment proﬁles were obtained for all modulated lncRNAs across tissues.
Globally, their expression levels and breadth of expression across tis-
sues was comparable to all GENCODEv7 lncRNAs (Suppl. Fig. 1F). Inter-
estingly, many upregulated lncRNAs were more expressed in adult
heart tissue as compared with downregulated and all GENCODEv7
lncRNAs. This supported the notion that upregulated lncRNAs could
promote a cardiac differentiated state, which was comparable to that
seen in the adult heart.
2.2. Identiﬁcation of high priority candidate lncRNAs
We manually selected eleven lncRNAs as high priority candidates
based on speciﬁc criteria, including the presence of an active
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adult human hearts, proximity to important coding and noncoding
genes, signiﬁcant modulation during CPC differentiation (log2FC N 0.5,
b−1.0) (Fig. 2A) and classiﬁcation subtype (Suppl. Fig. 2A). First of all,
we utilized a previously executed genome-wide ChIP-Seq screen [29],
and determined the occupancy proﬁles of enhancer-associated co-
activator proteins at candidate lncRNA loci in fetal and adult human
hearts. A number of candidates were associated with signiﬁcant p300/
CBP enrichment, and speciﬁcally within the fetal heart (Lnc-869, Lnc-
866, Lnc-518, Suppl. Fig. 2B), consistent with their expression in fetal
CPCs. These data also suggested that some of these lncRNAswere repre-
sentative of the previously described enhancer-associated lncRNAs [10,
11]. Furthermore, using previously published data sets, we assessed the
nuclear and cytoplasmic enrichment proﬁles of high priority candidates
in ENCODE validated subcellular fractions (Fig. 2B) [7]. The majority of
our candidates exhibited nuclear enrichment (e.g. Lnc-866). Interest-
ingly, several lncRNAs displayed different subcellular localization de-
pending on the cell type in which they were expressed (e.g. S-KANK).
Finally, we validated differential expression of all high priority candi-
dates in fetal CPCs one-week post differentiation using quantitative
RT-PCR (qRT-PCR) (Fig. 2C). Of note, three candidate lncRNAs that
were proximal to or overlapping coding genes (i.e. S-KANK1, AS-TNIK,
AS-LHX1) exhibited highly correlated expression patterns with their
corresponding coding genes, indicative of potential cis-regulation (Fig.
2D).2.3. CARMEN is a human super enhancer-associated lncRNA associated
with cardiac differentiation
Amongst the modulated lncRNAs, three transcripts, namely
ENST00000519898, ENST00000518014 and ENST00000509909, repre-
sent distinct annotated isoforms of a single lncRNA gene (Fig. 3A and
B). Importantly, CARMEN isoforms were predicted to have no apparent
coding potential using a variety of computational tools for (Suppl. Fig.
3A). In particular, we tested CARMEN using PhyloCSF (Suppl. Fig. 3A)
[30]. The resulting score of−44.5 (using default settings), below the ac-
cepted threshold of 28.34 for coding transcripts, indicates no evidence
for translation of any possible ORF. To further experimentally validate
this observation, we searched two experimental datasets investigating
the human proteome, neither of which record a peptide originating
from CARMEN [31,32]. This locus was of particular interest for several
reasons. Firstly, it was directly upstream of MIR-143 and -145, two im-
portant developmental miRNAs implicated in CPC speciﬁcation and dif-
ferentiation (Fig. 3A). Speciﬁcally, these two miRNAs were previously
shown to promote differentiation toward the smooth muscle cell line-
age [33,34]. Secondly, ChIP-analysis demonstrates that these transcripts
mapped to a highly active cardiac enhancer in both fetal and adult
human hearts (Fig. 3B). Notably, this region was shown to harbor a car-
diac SRF/NKX2.5-bound enhancer required for cardiac-speciﬁc expres-
sion of miR-143 and -145 during cardiac development [34].
Furthermore, this enhancer has been previously demonstrated to be a
Notch-responsive enhancer, capable of modulating miR-143 and -145
expressions in various developmental contexts [35]. Accordingly, the
enhancer was able to drive robust cardiac-speciﬁc activity in a mouse
transgenic reporter assays at E11.5 p.c. (Fig. 3C; images available using
enhancer ID: Hs1752 at the VISTA enhancer browser, http://enhancer.
lbl.gov/). Finally, using super enhancer (SE) tracks generated from
data obtained in the adult human left ventricle [14], we demonstrated
that this locus encompassed a cardiac SE. These ﬁndings indicated that
this genomic locus and its associated lncRNAs were potentiallyFig. 1. Global identiﬁcation of differentially expressed lncRNAs during cardiac differentiation. (A
differentiated (pink) CPCs. (B) Human CPCs derived from the fetal heart express differentiatio
ferentially expressed lncRNAs during cardiac differentiation. (D) Correlation based clustering o
lncRNAs in orientations relative to proximal coding genes. *P b 0.05, SEM. Scale bars: 20 μm (nimportant regulators of cardiac identity genes and pathways. We
named this gene CARMEN for (CAR)diac (M)esoderm (E)nhancer-asso-
ciated (N)oncoding RNA, and its individual isoforms CARMEN1,
CARMEN2 and CARMEN3 (Fig. 3B). We proceeded to quantify the abso-
lute expression of CARMEN isoforms using primers designed to distin-
guish individual transcripts (Suppl. Fig. 3B). All three isoforms were
expressed at relatively high levels and signiﬁcantly induced in differen-
tiating fetal CPCs (Fig. 3D), supporting a role during cardiac speciﬁcation
and differentiation for these SE-associated lncRNAs. Interestingly,MIR-
143 and -145weremodulated in an opposingmanner during differenti-
ation (Fig. 3E).
Evolutionary conservation supports the importance of CARMEN in
cardiac precursor cell differentiation. A long noncoding RNA,
(AK087736), is transcribed from the orthologous region of the mouse
genome, which we designate as the mouse ortholog (Fig. 4A). Interest-
ingly, the promoter region is highly conserved, supporting an important
role in the regulation of transcription at this locus. In themouse, another
annotated convergent lncRNA is present on the opposite strand. This
lncRNA, AK143260, has recently been demonstrated to be a cardiac
lncRNA named Braveheart (Bvht), critically required for progression of
nascent mesoderm toward the cardiac fate during cardiogenesis [18].
It is important to note that no ortholog of Bvht has been identiﬁed in
human.
We proceeded to quantify the expression of both Carmen and Bvht
during cardiogenesis in two independent murine models of cardiac
speciﬁcation and differentiation in vitro. We ﬁrst induced mouse em-
bryonic stem (ES) cells to differentiate using the hanging drop model
[36]. This model recapitulates embryonic cardiac development
in vitro, generating all appropriate cardiac lineages. We ﬁrst examined
the temporal gene expression patterns associated with pluripotency
(ES), cardiacmesoderm (MES), cardiac precursors (CPC) and differenti-
ated cardiomyocytes (CM) (Suppl. Fig. 4A). Upon differentiation, the
pluripotency markers Oct4 and Nanog were rapidly downregulated
(Suppl. Fig. 4B). This occurred concomitantly with the transient induc-
tion of cardiac mesoderm specifying TFs, Mesp1 and Eomes (Fig. 4B;
Suppl. Fig. 4B). Three core cardiac TFs, Nkx2.5, Gata4 and Islet1, which
specify CPCs and initiate the cardiac gene program, were signiﬁcantly
upregulated at the CPC stage (Fig. 4B; Suppl. Fig. 4B). Finally, this was
followed by the robust expression of cardiac differentiation and struc-
tural proteins,Myh6,Myh7 andMyl2 (Suppl. Fig. 4B). We then assessed
Carmen andBvht expression.Carmenwas induced between theMES and
CPC stages with maximal expression occurring in CPCs (Fig. 4C). Bvht
was initially downregulated between ES and MES stages, before subse-
quently being upregulated in CPCs and CMs (Fig. 4C), in agreementwith
previously published observations [18]. Altogether, these different ki-
netics of expression supported a role for Carmen during cardiac speciﬁ-
cation and differentiation of mouse ES cells. Importantly, Carmen
expression in the adult mouse heart was comparable to expression in
differentiated ES cell-derived CMs (Suppl. Fig. 4D).
We sought further support for these ﬁndings in another model of
cardiac differentiation using P19CL6 cells. These can readily be induced
to differentiate into beating cardiomyocytes upon induction by dimeth-
yl sulfoxide (DMSO) [37]. Indeed, differentiating P19CL6 cells recapitu-
lated cardiac differentiation, and demonstrated the expected change in
gene expression in pluripotency (Oct4, Nanog), MES (Mesp1, Eomes),
CPC (Gata4, Islet1) and CM (Myh6, Myl2) marker genes (Fig. 5). Meso-
dermal speciﬁcation occurred speciﬁcally between day 0 and day 2
while CPCs and CMs emerged between day 2 and day 4. Comparable
to their expression kinetics during ES differentiation, both Carmen and
Bvht were maximally expressed between the MES and CPC stages.) Quantitative RT-PCR analysis of differentiation marker genes in proliferating (blue) and
n markers 1 week after culture in differentiation medium. (C) Microarray heatmap of dif-
f individual samples based on lncRNA expression. (E) Number of differentially modulated
= 4).
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determined stage-speciﬁc activation of chromatin states at the locus in
the mouse. We took advantage of publicly available chromatin state
maps, generated using chromatin immunoprecipitation followed by se-
quencing (ChIP-Seq) in differentiating ES cells [38]. Analyses were exe-
cuted in pluripotent mouse ES cells (ES, i.e. Oct4-positive cells), at the
cardiac mesoderm stage (MES, i.e. Mesp1-positive cells), the cardiac
precursor stage (CPC, i.e. Nkx2.5-positive cells) and in differentiated
cardiomyocytes (CM, i.e. Myl2-positive cells). Assessment of
H3K27me3 and H3K4me3 (associated with inactive and active canoni-
cal promoters respectively), and H3K4me1 and H3K27Ac (associated
with poised and active enhancers respectively) allowed us to analyze
chromatin state transitions at the Carmen locus during cardiogenic dif-
ferentiation (Suppl. Fig. 4C). First of all, Carmen was associated with a
super enhancer-like signature as judged by the broad and high
H3K27Ac occupancy levels during cardiac differentiation. Maximal en-
hancer activity, as indicated by the peak of H3K27Ac enrichment, oc-
curred between the MES and CPC stages. Carmen expression therefore
correlated with enhancer activity, as recently observed for other fetal
cardiac enhancers active during cardiac differentiation [11]. Interesting-
ly Bvht was associated with a canonical promoter signature at its tran-
scriptional start site (i.e. H3K4me3), which was absent at the Carmen
locus. This suggests that Bvht should be classed as a promoter-
associated intergenic lncRNA. Altogether these data strongly support
Carmen being a bona ﬁde SE-associated lncRNA, whose expression cor-
relates with both the chromatin state activation of its associated en-
hancer in CPCs as well as with speciﬁcation and subsequent
differentiation of CPCs into cardiomyocytes.2.4. CARMEN controls cardiac speciﬁcation and differentiation in mouse
CPCs
To determine if Carmen actively regulated cardiac speciﬁcation and
differentiation, we stably transfected P19CL6 cells with a shRNAi
targeting Carmen. Cardiogenesis was induced in transfected cells by
DMSO addition. Four days following induction, loss-of-function resulted
in a complete block of Carmen expression (Fig. 5). Interestingly, Bvht in-
ductionwas also completely blocked upon Carmen silencing, suggesting
that Bvhtwas controlled by Carmen. In accordancewith the known roles
of Bvht in regulating the cardiogenic program, the expression of Mesp1,
the downstream cardiac TFs Gata4 and Islet1, and the CM-speciﬁc genes
Myl2,Myh6were severely inhibited by Carmen loss-of-function. In addi-
tion, Eomes, a key TF upstream ofMesp1 in the cardiac mesoderm spec-
iﬁcation pathway and the pluripotency regulators Oct4 andNanogwere
also affected by Carmen depletion. Previous work demonstrated that
Eomes and the pluripotency genes were not affected by Bvht knock-
down. These data therefore suggest the existence of feedback mecha-
nisms able to affect pluripotency (Oct4, Nanog) and early mesodermal
speciﬁcation (Eomes) that are dependent on Carmen expression.
To extend these ﬁndings in human cells, fetal CPCs were transfected
with modiﬁed antisense oligonucleotides (GapmeRs) targeting the
three human CARMEN isoforms. After 72 h, transfected proliferating
CPCs were cultured under differentiation conditions. Efﬁcient depletion
was observed in GapmeR-treated cells 10 days post induction of cardiac
differentiation (Fig. 6A). This depletionwas associatedwith a signiﬁcant
reduced expression of cardiac transcription factors and differentiation
makers, including GATA4, NKX2.5, TBX5, MYH6, MYH7, and TNNI (Fig.
6B). Furthermore CARMENdepletionwas associatedwith decreased ex-
pression of the smooth muscle cell marker, MYH11. Importantly,
CARMEN depletion was not associated with decreased expression ofFig. 2. Identiﬁcation of highpriority cardiac lncRNAs. (A)Microarray heatmapof differentially ex
lncRNAs. Blue indicates nuclear while red indicates cytoplasmic enrichment. (C) qRT-PCR analy
(D) Expression analysis of lncRNA candidates with proximal coding gene. LncRNA/protein codmiR-143 and -145, further supporting the notion that CARMEN isoforms
are not the precursor transcripts for thesemiRNAs (Fig. 6C). As a conse-
quence, CARMEN silencing impaired the capacity of human CPCs to pro-
duce differentiated cardiomyocytes (Fig. 6D). To further dissect the
roles of CARMEN and the proximal miRNAs in this differentiation pro-
cess, CARMEN-depleted cells were also co-transfected with MIR-143
and MIR-145 mimics. This led to increased expression of both miRNAs
in control and CARMEN-depleted cells. The predicted downregulation
of the prototypic miRNA targets ELK1 and KLF4 demonstrated efﬁcient
MIR mimic transfection (Fig. 6C). Importantly, and conﬁrming a
miRNA-independent role for CARMEN in cardiogenic differentiation,
MIRmimicswere not able to restore cardiogenic differentiation induced
by CARMEN knockdown. In contrast, expression of the smooth muscle
cell marker MYH11 was induced by MIR-143 and MIR-145 mimics, in
agreement with the known roles of the two miRNAs as promoters of
smooth muscle cell differentiation. Altogether, this indicates that
CARMEN is able to control cardiac speciﬁcation and differentiation inde-
pendently of MIR-143/145.
2.5. CARMEN exhibits cis-acting function, and interacts with SUZ12 and
EZH2
Based on the genomic overlapwith bona ﬁde cis-acting enhancer se-
quences and the lack of a canonical promoter signature at the CARMEN
transcriptional start site, we suspected that CARMEN enacted regulatory
activity akin to other recently described enhancer associated lncRNAs
[16–19]. In order to test this hypothesis, we constructed a plasmid, in
which CARMEN expression was under the control of a Doxycycline
(Dox)-inducible promoter (Fig. 7A). This promoter is completely inac-
tive in the absence of Dox. A ﬁreﬂy luciferase reporter gene under the
control of a basal SV40 promoter was then inserted directly down-
stream of the CARMEN expression cassette. A control vector was also
constructed containing a GFP sequence instead of CARMEN. The pres-
ence of CARMEN DNA in the construct resulted in signiﬁcant luciferase
activity, even in the absence of CARMEN transcription (Dox neg) indi-
cating the intrinsic enhancer activity of the locus. Crucially, induction
of CARMEN transcription by addition of Doxycycline caused additional
activation of luciferase activity. Thus, RNA from the CARMEN enhancer
contributed to stimulate luciferase expression (Fig. 7B). These results
support the idea that cis-enhancing activity of this enhancer locus is de-
pendent on the production of an associated lncRNA, i.e. CARMEN. Impor-
tantly, a number of recent reports have indicated that enhancer cis-
acting lncRNAs can also enact trans functions through interaction with
ubiquitously expressed chromatin-modifying complexes [19]. In partic-
ular, many lncRNAs have been shown to associate with le polycomb re-
pressive complex 2 (PRC2). We therefore investigated if Carmen could
physically interact with components of this complex in mouse embry-
onic stem cells. We performed RNA immunoprecipitation (RIP) assays,
in which RNA-protein complexes were immunoprecipitated with anti-
bodies speciﬁc to EZH2 and SUZ12 (Fig. 7C and D). We found that
Carmen was associated with both proteins, suggesting that Carmen
may have trans-repressive roles during cardiac differentiation.
2.6. CARMEN is modulated in cardiac disease and required for maintaining
a differentiated cardiac fate
Our data indicated that CARMEN was required for the speciﬁcation
and cardiac differentiation of pluripotent and cardiac precursor cells.
Furthermore, utilizing data from previous RNA-Seq based studies dem-
onstrated that this transcript was highly expressed in the adult mousepressed high priority candidate lncRNAs. (B) Subcellular location of highpriority candidate
sis of high priority candidates in proliferating (blue bar) and differentiated (pink bar) CPCs.
ing gene genomic orientation is illustrated above each graph. *P b 0.05, SEM (n = 4).
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Fig. 4. Carmen is differentially expressed duringmurine cardiac differentiation. (A) Carmen is highly conserved across vertebrate species. Comparative genomic alignment of 17 vertebrate
species to themouse genome (mm9) using conservation tracks available on the UCSC browser. (B–C)Mesp1, Gata4, Carmen and Braveheart are differentially expressed during cardiac dif-
ferentiation of mouse embryonic stem cells. *P b 0.05, SEM (n = 3).
105S. Ounzain et al. / Journal of Molecular and Cellular Cardiology 89 (2015) 98–112and human heart (not shown) [22]. We therefore investigated whether
CARMEN expressionwasmodulated in response to cardiac stress inmu-
rine models of heart disease and in the heart of human patients suffer-
ing from two different cardiac pathologies. We ﬁrst determined
expression in a mouse model of myocardial infarction. Fourteen days
after infarction, themyocardiumwas characterized by intense remodel-
ing anddecreased cardiac function (Suppl. Fig. 5A), and induction of car-
diac markers of stress (Fig. 8A). Carmen was signiﬁcantly upregulated
post myocardial infarction (Fig. 8A), supporting a role for Carmen in
adult heart homeostasis and cardiac remodeling.
To determine the potential roles of human CARMEN in cardiac dis-
ease, we examined its expression in two human heart pathologies, i.e.
idiopathic dilated cardiomyopathy (DCM) and aortic stenosis (AOS).
DCMpatients presented reduced cardiac functionwhereas AOS patients
demonstrated preserved function. In addition, cardiac dilation was evi-
dent in DCM patients and AOS patients were characterized by cardiacFig. 3. Identiﬁcation of CARMEN. (A) UCSC screenshot of the Human CARMEN locus with CARM
with a human super-enhancer as indicated by p300 occupancy; yellow box indicates sequences
assay, the enhancer fragment indicated by a black box drives reproducible cardiac expression in
143 and -145 during cardiac differentiation in proliferating (blue bar) and differentiated (pinkhypertrophy (Suppl. Fig. 5B and C; Suppl. Table S3). The stereotypical
cardiac stress marker NPPA was also signiﬁcantly upregulated in both
pathologies (Fig. 8B and C). We then assessed the expression of all
three human CARMEN isoforms. CARMEN3 was signiﬁcantly upregulat-
ed in both DCM and AOS whereas CARMEN1 and 2 were only induced
in AOS patients (Fig. 8B and C). We further searched for independent
validation of the relationship between CARMEN3 expression and cardiac
disease state. The Gtex project has produced RNA-Seq transcriptome
data from post mortem organs across a panel of human individuals
with medical history [39]. We examined therefore two relevant heart
tissues within Gtex, namely atrium and ventricle, for which 25 and 66
individual samples were respectively available. Of these two, CARMEN3
expression wasmarkedly higher in atria (P= 1.9e−09,Wilcoxon test)
(Fig. 8D). Next, we usedmedical data to separate patients based on a di-
agnosis of cardiovascular disease. Interestingly, hypertensive patients
demonstrated increased expression in atria (P = 0.008, Wilcox test)EN isoforms 1, 2 and 3 highlighted in blue. (B) The three CARMEN isoforms are associated
targeted by CARMEN speciﬁc GapmeRs. (C)When assessed in a transgenic mouse reporter
E11.5mouse embryos. (D); (E) Absolute qRT-PCR analysis of CARMEN isoforms andMIR-
bar) CPCs. *P b 0.05, SEM (n = 4).
Fig. 5. Knockdown of Carmen impacts upon cardiac speciﬁcation and differentiation.
(A) P19CL6 were transfected with Carmen-shRNA and then differentiated for 4 days in
1% DMSO. Target gene expression levels were assessed by qRT-PCR. *P b 0.05, SEM.
**P b 0.01, SEM (n = 3).
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0.1474, Wilcox test) (Suppl. Fig. 5D).
Finally, to further evaluate the importance of Carmen in cardiac ho-
meostasis, we analyzed the effects of Carmen depletion in primary mu-
rine cardiomyocytes. Cardiomyocytes were isolated from the neonatal
heart. At this stage, myocytes display signiﬁcant levels of early cardiac
markers such as Gata4 and Nkx2.5 but rapidly mature into beating
cardiomyocytes in vitro. Isolated cells were transfected with modiﬁed
antisense oligonucleotides (GapmeRs) targeting mouse Carmen (Fig.
8F). Carmenwasdepleted by approximately 50%,with this being accom-
panied by the signiﬁcant downregulation of key cardiac TFs and struc-
tural proteins (Gata4, Nkx2-5 andMyh6). This transcriptional response
was indicative of a dedifferentiation of isolated CMs upon Carmen si-
lencing, suggesting therefore that Carmen plays a critical role in main-
taining a differentiated cardiac fate in mature cardiomyocytes.
3. Discussion
Dynamic regulation of gene expression is critical for cell fate transi-
tions during cardiac lineage commitment, and faulty regulation can lead
to developmental failure and disease. A thorough understanding ofFig. 6. Knockdown of CARMEN impacts upon cardiac speciﬁcation and differentiation. Human f
mimics, and then differentiated for 10 days. Target gene expression levels of CARMEN (A), GA
and KLF4 (C) were assessed by qRT-PCR. (D) Decreased capacity to produced α-actinin-positivthese processes can facilitate the targeted derivation of important
cardiovascular lineages required for cell replacement therapies. Cardio-
vascular lineage speciﬁcation and differentiation is a multistep process
regulated by a network of transcription factors [3]. Though many of
the genetic factors that control cardiac development and CPC lineage
determination and differentiation are known, we suspect that lncRNAs
represent an additional layer of regulation [40]. Here, we identify hun-
dreds of differentially modulated human lncRNAs during cardiac differ-
entiation of isolated human fetal CPCs. Interestingly, many of these
validated candidates are mapping to bona ﬁde human fetal and adult
cardiac enhancers, suggesting they represent the newly identiﬁed
enhancer-associated lncRNA class [10,11]. We have recently demon-
strated that a signiﬁcant fraction of novelmurine cardiac polyadenylated
and multi-exonic lncRNAs are derived from developmental cardiac en-
hancers [11,22]. The human lncRNAs described here are comparable in
their chromatin state and likely cis-acting function. In support of this,
we ﬁnd that several human lncRNA candidates are highly correlated in
their expression with proximal coding genes. We further characterized
one of these candidate lncRNAs, which we named CARMEN. CARMEN is
highly conserved in mouse, and appears to be an important regulator
of cardiovascular cell speciﬁcation and differentiation. Furthermore,
CARMEN is derived from a human SE, which has been shown to be active
in the adult heart. Considering the master regulatory roles of SEs in
controlling key cell identity genes, we suspect that CARMEN represents
a novel SE-associated lncRNA critical for cell fate determination and
differentiation, akin to other recently described SE-derived lncRNAs
such as MyoD enhancer RNA and CCATL-1 [16,17].
Interestingly, CARMEN is proximal to an important developmental
miRNA locus, encoding the MIR-143 and -145. These miRNAs have
been previously shown to be crucial post-transcriptional regulators of
key pathways implicated in pluripotency and cardiovascular lineage
commitment [33,34]. It is important to emphasize that the CARMEN iso-
forms assessed here do not represent precursor transcripts for MIR-
143/-145. Indeed, previous analysis of promoter-speciﬁc histone modi-
ﬁcations and poly(A) signal frequencies demonstrate that CARMEN
transcript boundaries are well deﬁned [7]. The majority of cDNA and
EST fragments overlappingCARMEN terminate at the position annotated
by GENCODE, i.e. upstream of miR-143. In addition, a non-canonical
polyadenylation sequence is locatedwithin 20 nucleotides of the termi-
nation site. The end of CARMEN is also marked by an SVM-predicted
polyadenylation site [41]. Furthermore, MIR-143 and -145 expression
does not correlate with CARMEN expression during cardiac differentia-
tion, and CARMEN depletion does not lead to reduced miRNA expres-
sion. Most importantly, miRNA overexpression in CARMEN-depleted
fetal CPCs is not able to rescue the differentiation defect induced by
CARMEN knockdown, suggesting that CARMEN-mediated induction of
cardiogenesis is independent of the proximal miRNAs. Altogether,
these different pieces of evidence refute that CARMEN represents a pre-
cursor of the two miRNAs.
Mouse ES cells with deletions of both miR-143 and miR-145 have
been shown in previous studies not to phenocopy Bvht depleted cells
[18], supporting a miRNA-independent role for Bvht. In the mouse,
Bvht is necessary for the activation of a core cardiac gene network and
functions upstreamofMesp1 [18]. It regulates the cardiac gene network
during CMdifferentiation through interactingwith SUZ12, a component
of PRC2, suggesting that Bvhtmediates epigenetic regulation of cardiac
commitment. Bvht is also important for maintaining a cardiac identity
in neonatal CMs, as shown for Carmen. Our luciferase reporter assay pro-
vides support that the cis-acting regulatory activity of the enhancer
locus is potentiated by the active transcription of CARMEN, a ﬁnding
comparable with recently published ﬁndings for other lncRNAs [42].
We also ﬁnd that Carmen directly interacted with PRC2 through bothetal CPCs were transfected with CARMEN GapmeR, with or without MIRNA-143 and -145
TA4, NKX2.5, TBX5, MYH6 and MYH7, TNNNI, and Myh11 (B) andMIR-143, MIR-145, ELK1
e CMs in CARMEN-depleted fetal CPCs. *P b 0.05, SEM (n = 3). Scale bars: 20 μm.
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cis or trans is, however, currently not known. Potentially, Carmenmay,
like other cardiogenic lncRNAs such as Bvht and Fendrr, either compete
for PRC2 binding at speciﬁc loci during cardiac differentiation or actively
target PRC2 [18,19]. Our work suggests therefore that Carmenmediates
cardiac speciﬁcation and differentiation, in part through cis- and trans-
dependent epigenetic regulation,which appears to represent an emerg-
ing paradigm for lncRNAs.
The loss-of-function data suggest that Carmen is directly implicated
in the earliest steps of lineage commitment, able to control the expres-
sion of both pluripotency and cardiac mesodermal specifying genes.
Since the human CARMEN locus does not contain an ortholog of
mouse Bvht, it suggests that Bvht is dispensable for cardiac speciﬁcation
in human CPCs. The loss of Bvht in the human lineage represents an in-
teresting evolutionary event in species-speciﬁc heart developmental
pathways, which requires further investigation. In contrast, the fact
that CARMEN is conserved and expressed in human supports an evolu-
tionary conserved role in this process. Our work suggests that CARMEN
functions upstream of and in the same regulatory pathway as EOMES
andMESP1 in amiRNA-independent fashion, as a reprogramming factor
necessary for cardiac commitment and differentiation of CPCs. Impor-
tantly, EOMES andMESP1 can specify all cell types of the cardiovascular
lineage [43,44]. MESP1 is able to induce transdifferentiation of dermal
ﬁbroblasts into CPCs [45]. This indicates that CARMEN could also be a
critical factor for inducing somatic cell reprogramming toward a cardio-
vascular state. A number of recent studies have demonstrated that spe-
ciﬁc combinations of key cardiac TFs andmiRNAs are able to reprogram
cardiac ﬁbroblasts into mature CMs in vitro and in vivo [46–49]. This
represents a very attractive therapeutic strategy for the promotion of
cardiac regeneration. Our data suggest that CARMEN, in addition to
other lncRNAs identiﬁed in the present study, could represent interest-
ing cardiogenic reprogramming factors.
Pathological cardiac remodeling and the subsequent transition to
heart failure are typically associated with the re-activation of a fetal
gene program [1]. We have previously demonstrated that many devel-
opmental cardiac enhancer-associated lncRNAs are transcriptionally in-
duced in the remodeling and failing heart [11,22]. Interestingly, Carmen
is induced inmousemodels of cardiac disease, and human CARMEN iso-
forms are induced in AOS and DCM patients. Importantly, Carmen-
depleted cardiomyocytes demonstrate reduced expression of cell iden-
tity genes. Carmen expression appears therefore critical for maintaining
a differentiated state in cardiomyocytes. An increasing number of stud-
ies are beginning to illustrate the roles of lncRNAs in the adult remodel-
ing heart [20–23], supporting the notion that cardiac lncRNAs, including
CARMEN, could represent unique targets for modulating the cardiac
pathological response, and possibly promoting regeneration [40]. In-
deed, it is conceivable that increased CARMEN expression in the stressed
heart reﬂects upregulation in a subset of cardiac cells other than
cardiomyocytes, in particular CPCs. If proved to be true, CARMEN could
be involved in initiating a cardiogenic program in CPCs that are mobi-
lized in the adult heart upon damage. In a broader context, themanipu-
lation of super enhancer-associated lncRNAs represents a new avenue
for controlling the gene regulatory networks that neocardiogenesis in
the adult heart. CARMEN could potentially represent therefore an attrac-
tive therapeutic target for future regenerative and cell-based therapies.
4. Methods
Detailed methods can be found in Supplementary information.
4.1. Human p300 and super enhancer ChIP-Seq data
For ChIP-Seq analysis of human fetal and adult hearts, we utilized
previously published data sets [29,50]. Super enhancer annotations in
the adult left ventricle were obtained from [14].4.2. Cardiac injury models
Ligation of the left anterior descending artery —Myocardial infarc-
tion in mice was induced as previously described [22].
4.3. Echocardiography
Transthoracic echocardiographies were performed using a 30-MHz
probe and the Vevo 770 Ultrasound machine (VisualSonics, Toronto,
ON, Canada).
4.4. Primary cell cultures
Human fetal heart chambers and cardiac progenitor cells were iso-
lated as previously described [27].
4.5. Immunohistochemistry on fetal CPCs
Please refer to Supplementary material online.
4.6. RNA isolation, reverse transcription, end-point PCR and quantitative
PCR
Primer sequences for qRT-PCR are provided in Suppl. Table S1. For
TaqMan probe based qRT-PCR expression was analyzed using
ﬂuorescent-labeled TaqMan Probes (ABI), which are described in
Suppl. Table S1. Analysis was carried out using an ABI Prism 7500 cycler
and relative expression quantiﬁed using the ΔΔCt method. For end-
point PCR aliquots of PCR mixtures were taken during different cycles
for agarose gel analysis to determine linear range of ampliﬁcation. All
reactions were run on a 1.5% agarose gel stained with Ethidium
Bromide.
4.7. Cell culture and transfection
Please refer to Supplemental material online.
4.8. Differential expression analysis of lncRNAs
Total RNA (100 ng)was labeled using Low InputQuickAmpLabeling
kit (Agilent 5190-2305) following manufacturer instructions. mRNA
was reverse transcribed in the presence of T7-oligo-dT primer to pro-
duce cDNA. cDNA was then in vitro transcribed with T7 RNA polymer-
ase in the presence of Cy3-CTP to produce labeled cRNA. The labeled
cRNA was hybridized to the Agilent SurePrint G3 gene expression
8x60K microarray according to the manufacturer's protocol (Agilent
SurePrint 8 × 60 nt technology). The arrays were washed, and scanned
on an Agilent G2565CAmicroarray scanner at 100% PMT and 3um reso-
lution. Intensity data was extracted using the Feature Extraction soft-
ware (Agilent). Differentially expressed microarray probes were
identiﬁed using the limma package in R comparing microarray data
from 3 proliferating and 3 differentiating cell cultures. Data sets have
been deposited in the Gene Expression Omnibus Database under acces-
sion number (pending).
4.9. LncRNA analysis
Phastcons data: Base-level mean PhastCons scores were calculated
across the indicated genomic features [7].
4.10. Subcellular localization analysis
Nuclear, Cytoplasmic and Chromatin RNAseq data from human cell
lines were obtained from ENCODE [51]. Localization of transcripts was
estimated by the ratio of RPKM (reads per kilobase per million mapped
reads) values, with the condition that both valuesmust have a non-zero
Fig. 7.CARMEN is a cis-acting regulatory factor and interactswith PRC2. (A) Schematic representation of luciferase-lncRNA reporter constructs used to probe cis-acting function of CARMEN.
(B) Relative luciferase activity of reporter plasmidswith andwithout Doxycycline supplementation. (C andD) RNA Immunoprecipitation (RIP) of lncRNAs using anti-Suz12 and anti-EZH2
antibodies. Black bar represents control IgG and blue bar represents the indicated speciﬁc antibody. The indicated immunoprecipitated transcripts were quantiﬁed by qRT-PCR *P b 0.05,
SEM (n = 3–5).
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value (Irreproducible Discovery Rate) of 0.1 [7].4.11. Protein-coding potential
We used a series of widely used tools to evaluate protein-coding po-
tential of CARMEN isoforms (ENST00000505254, ENST00000518014)
using default settings, with the indicated cutoffs. CNCI [52]: N0, CPAT
(PMID:23335781): N0.43, CPC [53]: N0.54, iSeeRNA [54]: b0.71,
PhyloCSF [30]: N28.34 and RNACode [55]: N37.55. All methods indicate
non-protein coding status for both transcript isoforms.4.12. Cross-species screening pipeline
Please refer to Supplemental material online.4.13. CARMEN expression in Gtex samples
Tissue RNAseq quantiﬁcations were obtained from the Broad Insti-
tute in the form of gene-level RPKM [39].4.14. Chromatin states
To analyze the presence of chromatin marker peaks at pro-
moters during cardiac differentiation of mouse embryonic stem
cells, we used publicly available data published by Wamstad et al.
[38].4.15. Embryonic stem cell culture and differentiation
Mouse embryonic stem (ES) cells were differentiated into CMs as
previously described [36].4.16. P19CL6 cell culture and transfection
P19CL6 cells (RCB2318, RIKEN Cell Bank, Japan) were cultured in
DMEM with 10% FCS and antibiotics. Transfection of P19CL6 cells with
pLKO.1-puro-UbC-Tag635™ (containing shRNAi, Sigma Aldrich) was
performed with Lipofectamine 2000 (Invitrogen) according to
manufacturer's instructions. P19CL6was a kind gift of Dr. Elizabeth Rob-
ertson, University of Oxford, UK.
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All human material was obtained during routine sampling used for
clinical purposes or after obtaining informed consent, stored in a
coded way and available for research purposes in accordance with the
Declaration of Helsinki and the ethical committee at Maastricht Univer-
sityMedical Center. For further details please refer to Supplementalma-
terial online.4.18. CARMEN LncRNA cloning
Human CARMEN1 was ampliﬁed from the FBI-1 cDNA template
using primers C222F (TACCGAGCTCGGATCCtcagtgccagctgcttaaaa) and
C222R (CTGGACTAGTGGATCCaggcacagtgttagagtttgct) with Expand po-
lymerase (Roche) (PCR conditions: annealing 60 °C, extension 3 min,
1.5 mM Mg, 40 cycles ampliﬁcation) and cloned into BamHI digested
plasmid pcDNA as described [56]. Human CARMEN1 insert was
subcloned into inducible plasmid pTretight-SV40-luciferase (*pTre-
tight vector from Clontech in which we added a SV40-luciferase ORF).
All the clones were checked by Sanger sequencing. (*pTre-tight vector
was gift from Susanna de la Luna lab).4.19. Luciferase assay
We performed luciferase assay using dual-luciferase reporter kit
(Promega) following standard protocols.4.20. RNA immunoprecipitation (RIP)
Cells were detached with Accutase (Millipore), crosslinked in 1%
formaldehyde for 15 min and quenched with 2.5 M glycine for 5 min.
The cell pellet was resuspended in modiﬁed RIPA buffer (150 mM
NaCl, 50 mM Tris, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) sup-
plemented with RNase inhibitor Superase.In (Ambion) and Complete
protease inhibitor (Roche). The cell suspension was brieﬂy sonicated
at low amplitude for 5 × 30 s cycles using a Bioruptor sonicator to lyse
nuclei. Cell debris was removed by centrifugation at 4 °C, precleared
with Protein G dynal beads (Invitrogen) before adding the respective
antibodies pre-bound with Protein G dynal beads for 3 h at RT. 25 μg
of rabbit anti-SUZ12 antibody (Abcam ab12073) or control rabbit IgG
antibody was used for each RIP. Beads were then washed 3 times in
modiﬁed RIPA buffer, and twice in high salt RIPA buffer (1 M NaCl,
50 mM Tris, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40). Crosslinks
were reversed and proteins were digested with Proteinase K
(Invitrogen) at 65 °C for 2 h. RNA was extracted in Trizol (Invitrogen)
following the manufacturer's instructions. RNA was then reverse tran-
scribed using High Capacity cDNA kit (Ambion) and used for quantita-
tive PCR (RIP-qPCR).4.21. Statistical analysis
Data throughout the paper are expressed as mean ± SEM. One way
ANOVA was used to test signiﬁcance of data comparisons between ex-
perimental groups, with P values b 0.05 were considered signiﬁcant.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2015.09.016.Fig. 8.Dysregulation ofCARMEN in cardiac pathology. (A) qRT-PCRanalysis ofCarmen and classic
hearts. (B) qRT-PCR analysis of CARMEN1, 2 and 3, andNPPA in cardiac biopsies from patients su
from patients suffering from AOS. (D) Gtex-derived RNA-Seq-based CARMEN3 expression in hu
from patients suffering from hypertension. (F) Mouse neonatal CMs were transfected with Ga
transfection and assayed for Carmen, Nkx2-5, Gata4,Myh6 andMyh7 expression. *P b 0.05, SEMSources of funding
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